Curcumin effects on the prevention of peripheral neuropathy-induced by chemotherapy regimen containing paclitaxel in breast cancer patients; a randomized, double blinded and placebo-controlled clinical trial

Esfahan University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新: 2024年3月6日

试验速览

暂无简介。

•All adult women (18 years and older and less than 65 years old) with non-metastatic breast cancer who received paclitaxel at a dose of 175 mg/m2 every 3 weeks for 4 courses after completing an anthracycline-containing regimen for the first time in the treatment process (New case patients).
•The patient must have compliance in taking medication for at least 8 weeks and have enough ability to swallow and consume nanocurcumin capsules orally.
•Patients should have the necessary literacy to fill in the questionnairesand also have the necessary cooperation in performing neurological tests.
•Patients who do not have any history of liver and kidney failure.

•Patients with a history of any peripheral neuropathy
•Patients with a history of coronary artery disease and peripheral vascular disease
•All diabetic patients
•Pregnancy and breastfeeding
•taking anticonvulsant drugs, Tricyclic antidepressants, other neuropathic pain relievers such as duloxetine
•Chronic use of cigarettes, drugs or alcohol
•Patients with a history of peripheral neuropathy (eg, hereditary, with nutritional factors and paraneoplastic causes)
•Those who have received chemotherapy for another malignancy in the past.
•Metastasis to the central nervous system or any neurological involvement due to metastasis or tumor pressure
•Users of anti-platelet drugs such as aspirin, etc. and oral and injectable anti-thrombosis

发起方